Latest News and Press Releases

CT-P72/ABP-102 poster selected as one of the Top 150 abstracts out of more than 1,300 submissions at SITC 2025 CT-P72/ABP-102 demonstrates potent and selective anti-tumor activity in HER2-high models,...

Achieved ~60% reduction in operating costs through a focused cost optimization plan DiversImmune® platform positioned to unlock additional pipeline value Reverse stock split supports Nasdaq...

Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager

WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and...

WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and...

Business combination closed November 13, 2024Raised $10 million of gross proceeds in connection with the business combinationAgreements are in place with Yorkville for up to a $50 million standby...

매사추세츠주 우번 & 뉴욕, Jan. 23, 2024 (GLOBE NEWSWIRE) -- 차세대 항체 치료제를 통해 치명적인 중증 질환에 직면한 인류의 삶을 개선해 나간다는 사명을 갖고 있는 Abpro Corporation (이하 "Abpro")와 특수목적 인수기업인 Atlantic Coastal Acquisition Corp. II (나스닥:...

WOBURN, Mass. and NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Abpro Corporation (“Abpro”), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening...

Preclinical pseudovirus data and structural modeling shows ABP 310 retains activity and potency against the SARS-CoV-2 Omicron variant mutationsABP 310 EUA possible as early as 2022 WOBURN, Mass.,...

Data showed reduction of neovascular lesion formation and vascular leakage in a rodent model of choroidal neovascularizationABP201 performed equally or better than aflibercept in lesion inhibition and...